Clinical Trials
2 trialsNCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT02338050 2015-09-16
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
Phase 2 Terminated